BEW Engg

- There is no explicit mention of any current or future fundraising through debt or equity in the provided transcript. - However, the company is targeting a 20% reduction in debt to enhance balance sheet strength and cash flow visibility. - There is no discussion about raising new equity or taking on new debt for expansion or operational needs in the current or upcoming fiscal years. - The focus appears to be on operational efficiency, capacity expansion, and improving working capital cycles rather than raising fresh capital.

- BEW Engineering has recently completed an expansion of its manufacturing facility. - The expansion was driven by current capacity utilization at around 90%, requiring more space for manufacturing and raw material storage. - The additional capacity is expected to enable revenue growth potential up to Rs. 300 crores over the next 2-3 years without the need for further capacity addition. - Management is confident in timely delivering orders due to the expanded facility nearing completion. - Going forward, the company sees good traction and CAPEX ordering from key sectors like Pharmaceuticals and Agro Chemicals. - There is no specific mention of fresh strategic investments or new capital expenditure projects in the immediate future beyond the recently completed expansion. - The focus is on leveraging the expanded capacity and operational efficiencies for growth and improving working capital cycles.

- Targeting revenue of around Rs. 175 crores for FY '26, with confidence due to a strong current order book of Rs. 80 crores and positive CAPEX trends in Pharma, Agro Chemicals, and Specialty Chemicals sectors. - Expect gradual growth in EBITDA margins from current levels (~15%) towards 20%-22% by FY '27, contingent on stable market conditions. - Capacity expansion nearly doubling production capacity, enabling the company to target Rs. 300 crores revenue in 2-3 years without adding new capacity. - Strong focus on building order book, especially from Pharma and Agro Chemicals, which are anticipated to be key growth drivers. - New orders from reputed pharma customers and market traction seen over past 2 months. - Strategic efforts on export growth, especially in Africa, Japan, Middle East, South Africa, Israel, and Russia. - Operational efficiencies and inventory cycle normalization expected to support growth and margin improvements.

- Revenue target is around Rs. 175 crore for FY '26, with a potential to reach Rs. 300 crore by FY '27 due to expanded capacity. - EBITDA margin expected to gradually grow from 15% in FY '26, aiming for 20%-22% in FY '27 if market conditions remain stable. - Profit after tax showed a decrease in FY '25 but is expected to improve with better order flow and operational efficiencies. - The company anticipates strong order inflows particularly from Pharma and Agro Chemical sectors, supporting growth. - Earnings per share (EPS) decreased from Rs. 46.56 in FY '24 to Rs. 9.30 in FY '25 but with revenue growth and margin expansion, EPS is expected to improve. - Inventory and working capital normalization strategies are in place to enhance margins and cash flow going forward.

- Current order book stands at around Rs. 80 crores as of end of the last reported period (March 31, 2025). - Recent months have seen good traction in orders, especially from the Pharma and Agro Chemicals sectors. - The company is witnessing increased order inflows and expects the order book to grow due to ongoing CAPEX activities at customer end. - With expanded manufacturing capacity nearing completion, the company is confident in taking and delivering more orders promptly. - The management is optimistic about steady order flow ahead, particularly from Pharma, Agro, and Specialty Chemicals sectors. - Target revenue for FY '26 is Rs. 175 crores, indicating confidence in order conversion and additions. - For the next 2-3 years, the company aims to reach Rs. 300 crores in revenue leveraging current capacities.